Ventyx Biosciences, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.ventyxbio.com

Market Cap $211.21M
PE -1
Debt $NaN
Cash $62.74M
EV $NaN
FCF -$159.73M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$152.52M
EBIT	-$151.32M
ROE	-55%
ROA	-50%
FCF	-$159.73M
Equity	$278.77M
Growth Stability	1
PE	-1.38
PB	0.76
P/FCF	-1.32
Price/Cash	0.3
Equity CAGR	-1%
Earnings Growth YoY	-35%

Earnings Growth QoQ	10%
Equity CAGR 5Y	-1%
Equity CAGR 3Y	-1%
Market Cap	$211.21M
Assets	$301.10M
Cash	$62.74M
Shares Outstanding	67.69M
Working Capital	277.11M
Current Ratio	23.52
Shares Growth 3y	12%
Equity Growth QoQ	-1%
Equity Growth YoY	-2%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

SEC Filings

Direct access to Ventyx Biosciences, Inc. (VTYX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Ventyx Biosciences, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Ventyx Biosciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Ventyx Biosciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Ventyx Biosciences, Inc..

Years

Calculation mode

= -$1.6B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$160M	-$160M	-$160M	-$160M	-$160M	-$160M	-$160M	-$160M	-$160M	-$160M	-$160M	-$1.6B
DCF		-$145M	-$132M	-$120M	-$109M	-$99M	-$90M	-$82M	-$75M	-$68M	-$62M	-$616M
Value	-$1.6B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-
ROA	-	-23%	-29%	-69%	-50%
ROE	-	-31%	-31%	-79%	-55%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-
Debt over Equity	-	-	-	-	-
Growth Stability	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-
Earnings YoY growth	-	203%	27%	78%	-
Equity YoY growth	-	-1K%	27%	-31%	-1%
FCF YoY growth	-	-	155%	69%	-